| CXHL2401263 | BPI-452080片 | BPI-452080 | Tablet | Chemical Drugs(1) | New Drug Application | 2024-11-21 | | Betta Pharmaceuticals Co Ltd | | | view |
| CXHL2401264 | BPI-452080片 | BPI-452080 | Tablet | Chemical Drugs(1) | New Drug Application | 2024-11-21 | | Betta Pharmaceuticals Co Ltd | | | view |
| CXHL2401265 | BPI-452080片 | BPI-452080 | Tablet | Chemical Drugs(1) | New Drug Application | 2024-11-21 | | Betta Pharmaceuticals Co Ltd | | | view |
| CXSL2400603 | 注射用MCLA-129 | MCLA-129 | Lyophilized | Biological Products(1) | New Drug Application | 2024-09-11 | | Betta Pharmaceuticals Co Ltd | | | view |
| CXHL2400677 | CFT8919胶囊 | CFT-8919 | Capsule | Chemical Drugs(1) | New Drug Application | 2024-07-10 | | Betta Pharmaceuticals Co Ltd | | | view |
| CXHL2400676 | CFT8919胶囊 | CFT-8919 | Capsule | Chemical Drugs(1) | New Drug Application | 2024-07-10 | | Betta Pharmaceuticals Co Ltd | | | view |
| CXHS2400039 | 酒石酸泰贝西利胶囊 | BPI-16350 | Capsule | Chemical Drugs(1) | New Drug Application | 2024-05-01 | | Betta Pharmaceuticals Co Ltd | | | view |
| CXHB2400014 | BPI-460372片 | BPI-460372 | Tablet | Chemical Drugs(1) | Supplementary Application | 2024-01-11 | | Betta Pharmaceuticals Co Ltd | | | view |
| CXHL2400013 | BPI-221351片 | BPI-221351 | Tablet | Chemical Drugs(1) | New Drug Application | 2024-01-05 | | Betta Pharmaceuticals Co Ltd | | | view |
| CXHL2400011 | BPI-520105片 | BPI-520105 | Tablet | Chemical Drugs(1) | New Drug Application | 2024-01-05 | | Betta Pharmaceuticals Co Ltd | | | view |
| CXHL2400014 | BPI-221351片 | BPI-221351 | Tablet | Chemical Drugs(1) | New Drug Application | 2024-01-05 | | Betta Pharmaceuticals Co Ltd | | | view |
| CXHL2400010 | BPI-520105片 | BPI-520105 | Tablet | Chemical Drugs(1) | New Drug Application | 2024-01-05 | | Betta Pharmaceuticals Co Ltd | | | view |
| CXHL2400012 | BPI-520105片 | BPI-520105 | Tablet | Chemical Drugs(1) | New Drug Application | 2024-01-05 | | Betta Pharmaceuticals Co Ltd | | | view |
| CXHB2300161 | BPI-452080片 | BPI-452080 | Tablet | Chemical Drugs(1) | Supplementary Application | 2023-08-17 | | Betta Pharmaceuticals Co Ltd | | | view |
| CXHL2300495 | 甲磺酸贝福替尼胶囊 | Befotertinib Mesylate | Capsule | Chemical Drugs(1) | New Drug Application | 2023-05-09 | | Betta Pharmaceuticals Co Ltd | | | view |
| CXSL2300322 | 注射用MCLA-129 | MCLA-129 | Lyophilized | Biological Products(1) | New Drug Application | 2023-05-09 | | Betta Pharmaceuticals Co Ltd | | | view |
| CXHL2300494 | 甲磺酸贝福替尼胶囊 | Befotertinib Mesylate | Capsule | Chemical Drugs(1) | New Drug Application | 2023-05-09 | | Betta Pharmaceuticals Co Ltd | | | view |
| CXHB2300062 | BPI-421286胶囊 | BPI-421286 | Capsule | Chemical Drugs(1) | Supplementary Application | 2023-03-14 | | Betta Pharmaceuticals Co Ltd | | | view |
| CXHB2300061 | BPI-421286胶囊 | BPI-421286 | Capsule | Chemical Drugs(1) | Supplementary Application | 2023-03-14 | | Betta Pharmaceuticals Co Ltd | | | view |
| CXHS2300015 | 甲磺酸贝福替尼胶囊 | Befotertinib Mesylate | Capsule | Chemical Drugs(1) | New Drug Application | 2023-01-20 | | Betta Pharmaceuticals Co Ltd | | | view |
